# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $24 price target.
Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc ...
HC Wainwright & Co. analyst Ed Arce upgrades Cidara Therapeutics (NASDAQ:CDTX) from Neutral to Buy and announces $24 pri...
Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Overweight.
Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $25 price target.